Fingerprint
Dive into the research topics of 'MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure
R. Dreicer, W. M. Stadler, F. R. Ahmann, T. Whiteside, N. Bizouarne, B. Acres, J. M. Limacher, P. Squiban, A. Pantuck
Research output: Contribution to journal › Article › peer-review
56
Scopus
citations